Literature DB >> 21257245

Morphometric and biological characterization of biofilm in tunneled hemodialysis catheters.

Steven M Jones1, Pietro Ravani, Brenda R Hemmelgarn, Daniel Muruve, Jennifer M Macrae.   

Abstract

BACKGROUND: Bacterial biofilm formation on hemodialysis tunneled cuffed catheters is under-recognized. We studied biofilm characteristics in patients with and without catheter-related bloodstream infection, accounting for catheter locking solution (citrate 4% or heparin 1:1,000). STUDY
DESIGN: Prospective observational study. SETTING & PARTICIPANTS: 30 HD patients for whom the tunneled cuffed catheter was removed for either noninfectious reasons (n = 19) or bacteremia (n = 11). PREDICTORS: Bacteremia and catheter locking solution. OUTCOMES & MEASUREMENTS: Bacteria density in the biofilm, catheter luminal surface covered by biofilm, biofilm thickness, and exopolysaccharide content.
RESULTS: Biofilm was present in all catheters. Overall, bacteria density, catheter surface coverage, biofilm thickness, and exopolysaccharide content were significantly higher in catheters from patients with bacteremia (5.3 [95% CI, 3.4-7.2] colony-forming unit [CFU]/mL; 47% [95% CI, 34%-60%]; 41 [95% CI, 26-55] μm; and 29.4% [95% CI, 20.1%-38.6%], respectively) than from patients without bacteremia (3.7 [95% CI, 3.6-3.8] CFU/mL; 17% [95% CI, 16%-19%]; 8.6 [95% CI, 7.3-9.8] μm; and 5.3% [95% CI, 3.7%-6.8%], respectively). However, all biofilm parameters were lower in catheters from patients with bacteremia when citrate was used as locking agent. Furthermore, bacteria density (0.08 [95% CI, 0.02-0.13] CFU/mL/3 cm), biofilm thickness (1.4 [95% CI, 0.8-2.1] μm/3 cm), and surface coverage (2.2% [95% CI, 1.8%-2.7%]/3 cm) decreased across the length of the catheter from tip to hub. LIMITATIONS: Observational study design, small numbers of patients, use of prevalent catheters.
CONCLUSION: Biofilms are present in all tunneled cuffed catheters. However, the extent of the biofilm varied by the presence of bacteremia and type of locking solution. This method could be used to explore preventative measures.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21257245     DOI: 10.1053/j.ajkd.2010.10.053

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

Review 1.  Associations between hemodialysis access type and clinical outcomes: a systematic review.

Authors:  Pietro Ravani; Suetonia C Palmer; Matthew J Oliver; Robert R Quinn; Jennifer M MacRae; Davina J Tai; Neesh I Pannu; Chandra Thomas; Brenda R Hemmelgarn; Jonathan C Craig; Braden Manns; Marcello Tonelli; Giovanni F M Strippoli; Matthew T James
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

2.  Examining the Association between Hemodialysis Access Type and Mortality: The Role of Access Complications.

Authors:  Pietro Ravani; Robert Quinn; Matthew Oliver; Bruce Robinson; Ronald Pisoni; Neesh Pannu; Jennifer MacRae; Braden Manns; Brenda Hemmelgarn; Matthew James; Marcello Tonelli; Brenda Gillespie
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-18       Impact factor: 8.237

3.  Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution.

Authors:  Brenda R Hemmelgarn; Braden J Manns; Steven D Soroka; Adeera Levin; Jennifer MacRae; Karthik Tennankore; Jo-Anne S Wilson; Robert G Weaver; Pietro Ravani; Robert R Quinn; Marcello Tonelli; Mercedeh Kiaii; Paula Mossop; Nairne Scott-Douglas
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-15       Impact factor: 8.237

4.  Temporal risk profile for infectious and noninfectious complications of hemodialysis access.

Authors:  Pietro Ravani; Brenda W Gillespie; Robert Ross Quinn; Jennifer MacRae; Braden Manns; David Mendelssohn; Marcello Tonelli; Brenda Hemmelgarn; Matthew James; Neesh Pannu; Bruce M Robinson; Xin Zhang; Ronald Pisoni
Journal:  J Am Soc Nephrol       Date:  2013-07-11       Impact factor: 10.121

5.  Minimizing hemodialysis catheter dysfunction: an ounce of prevention.

Authors:  Timmy Lee; Charmaine Lok; Miguel Vazquez; Louise Moist; Ivan Maya; Michele Mokrzycki
Journal:  Int J Nephrol       Date:  2012-02-19

6.  Association Between Vascular Access Dysfunction and Subsequent Major Adverse Cardiovascular Events in Patients on Hemodialysis: A Population-Based Nested Case-Control Study.

Authors:  Te-Hui Kuo; Chien-Tzu Tseng; Wei-Hung Lin; Jo-Yen Chao; Wei-Ming Wang; Chung-Yi Li; Ming-Cheng Wang
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

7.  Practical Aspects of Nontunneled and Tunneled Hemodialysis Catheters.

Authors:  Edward Clark; Joanne Kappel; Jennifer MacRae; Christine Dipchand; Swapnil Hiremath; Mercedeh Kiaii; Charmaine Lok; Louise Moist; Matthew Oliver; Lisa M Miller
Journal:  Can J Kidney Health Dis       Date:  2016-09-27

8.  Effect of national pre-ESRD care program on expenditures and mortality in incident dialysis patients: A population-based study.

Authors:  Ming-Yen Lin; Li-Jen Cheng; Yi-Wen Chiu; Hui-Min Hsieh; Ping-Hsun Wu; Yi-Ting Lin; Shu-Li Wang; Feng-Xuan Jian; Chih Cheng Hsu; Shu-An Yang; Huei-Lan Lee; Shang-Jyh Hwang
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

9.  Clinical Outcomes and Risk Factors for Tunneled Hemodialysis Catheter-Related Bloodstream Infections.

Authors:  Kylie Martin; Yves S Poy Lorenzo; Po Yee Mia Leung; Sheri Chung; Emmet O'flaherty; Nuala Barker; Francesco Ierino
Journal:  Open Forum Infect Dis       Date:  2020-04-11       Impact factor: 3.835

10.  Deciphering the Contribution of Biofilm to the Pathogenesis of Peritoneal Dialysis Infections: Characterization and Microbial Behaviour on Dialysis Fluids.

Authors:  Joana Sampaio; Diana Machado; Ana Marta Gomes; Idalina Machado; Cledir Santos; Nelson Lima; Maria João Carvalho; António Cabrita; Anabela Rodrigues; Margarida Martins
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.